A retrospective analysis of the short-term effects of olanzapine and quetiapine on weight and body mass index in children and adolescents

Pharmacotherapy

Volumn 24, Issue 7 I, 2004, Pages 824-830

  Patel, Nick C ^a,b   Kistler, Jennifer S ^c   James, Elizabeth B ^a   Crismon, M Lynn ^a,b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b Texas Dept Mental Hlth Mental R   (United States)

^c Broughton Hospital   (United States)

Author keywords

Adolescents; Atypical antipsychotics; Body mass index; Children; Olanzapine; Quetiapine; Weight

Indexed keywords

AMPHETAMINE DERIVATIVE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; LITHIUM; METHYLPHENIDATE; OLANZAPINE; OXCARBAZEPINE; PSYCHOSTIMULANT AGENT; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; VALPROATE SEMISODIUM; VALPROIC ACID;

ADOLESCENT; ARTICLE; BODY MASS; BODY WEIGHT; CHILD; DRUG CHOICE; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; OBESITY; RETROSPECTIVE STUDY; UNITED STATES; WEIGHT GAIN;

ADOLESCENT; BENZODIAZEPINES; BODY MASS INDEX; CHILD; DIBENZOTHIAZEPINES; FEMALE; HUMANS; MALE; RETROSPECTIVE STUDIES; WEIGHT GAIN;

EID: 3042820506     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.9.824.36091     Document Type: Article

References (32)

1. Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA 2002;288:1728-32.
2. Allison DB, Fontaine KR, Heo M, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999;60:215-20.
3. Coodin S. Body mass index in persons with schizophrenia. Can J Psychiatty 2001;46:549-55.
4. Allison DB, Mentore JL, Moonseong H. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96.
5. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001;62(suppl 7):22-31.
6. Blin O, Micallef J. Antipsychotic-associated weight gain and clinical outcome parameters. J Clin Psychiatry 2001;62(suppl 7):11-21.
7. Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999;60:358-63.
8. Casey DE, Zorn SH. The pharmacology of weight gain with antipsychotics. J Clin Psychiatry 2001;62(suppl 7):4-10.
9. Patel NC, Sanchez RJ, Johnsrud MT, Crismon ML. Trends in antipsychotic use in a Texas Medicaid population of children and adolescents: 1996 to 2000. J Child Adolesc Psychopharmacol 2002;12:221-9.
10. Kumra S, Jacobsen LK, Lenane M, et al. Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents. J Am Acad Child Adolesc Psychiatry 1998;37:377-85.
11. Findling RL, McNamara NK, Youngstrom EA, et al. A prospective, open-label trial of olanzapine in adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 2003;42:170-5.
12. Dittmann RW, Hagenah U, Junghanß J, et al. Multicenter study of adolescents with schizophrenia: efficacy and safety of olanzapine [poster]. Presented at the 43rd annual meeting of the new clinical drug evaluation unit, Boca Raton, FL, May 27-30, 2003.
13. Frazier JA, Biederman J, Tohen M, et al. A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 2001;11:239-50.
14. McConville BJ, Arvanitis LA, Thyrum PT, et al. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. J Clin Psychiatry 2000;61:252-60.
15. Shaw JA, Pascal S, Sharma RK, et al. A study of quetiapine: efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol 2001;11:415-24.
16. Grcevich S, Melamed L, Richards R, et al. Comparative side effects of atypical antipsychotics in children and adolescents. Presented at the 8th biennial meeting of the international congress on schizophrenia research, Whistler, British Columbia, Canada, April 28-May 2, 2001.
17. Ogden CL, Kuczmarski RJ, Flegal KM, et al. Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics 2002;109:45-60.
18. Worrell JA, Marken PA, Beckman SE, Ruehter VL. Atypical antipsychotic agents: a critical review. Am J Health-Syst Pharm 2000;57:238-55.
19. Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 2003;64:598-604.
20. Took KJ, Buck BL, Paradise NF, El-Dadah M. Quetiapine as an alternative to risperidone in children and adolescents with the side effect of weight gain [poster]. Presented at the 52nd institute on psychiatric services, American Psychiatric Association, Philadelphia, PA, October 25-29, 2000.
21. Arvanitis LA, Miller BG, for the Seroquel Trial 13 Study Group. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-46.
22. Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicentre, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996;16:158-69.
23. Peuskens J. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997;96:265-73.
24. Small JG, Hirsch SR, Arvanitis LA. Quetiapine in patients with schizophrenia. Arch Gen Psychiatry 1997;54:549-57.
25. Nemeroff CB. Dosing the antipsychotic medication olanzapine. J Clin Psychiatry 1997;58(suppl 10):45-9.
26. Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizo-affective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-65.
27. Umbricht DS, Pollack S, Kane JM. Clozapine and weight gain. J Clin Psychiatry 1994;55(suppl B):157-60.
28. Wetterling T, MuBigbrodt HE. Weight gain: side effect of atypical neuroleptics? J Clin Psychopharmacol 1999;19:316-21.
29. Correll CU, Parikh U, Kane J, Malhotra A. Atypical antipsychotic-induced nutritional and metabolic effects during development [poster]. Presented at the 50th anniversary meeting of the American Academy of Child and Adolescent Psychiatry, Miami Beach, FL, October 14-19, 2003.
30. Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 2001;62:231-8.
31. Devlin MJ, Yanovski SZ, Wilson GT. Obesity: what mental health professionals need to know. Am J Psychiatry 2000;157:854-66.
32. Aquila R. Management of weight gain in patients with schizophrenia. J Clin Psychiatry 2002;63(suppl 4):33-6.